Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial.
We report on two features of the early termination of the studies of ocular complications of AIDS monoclonal antibody cytomegalovirus retinitis trial: one related to the deliberative process of the treatment effects monitoring body (the policy and data monitoring board [PDMB]) and the other related to the relationships among the PDMB, the investigators, and the joint sponsors (the National Institutes of Health and a pharmaceutical company). The PDMB was challenged with reconciling internally inconsistent safety and mortality data and determining the weight to give mortality data from other concurrently running trials. The coordinating center faced a challenge in negotiating how to communicate results from a jointly sponsored trial. Early resolution of certain organizational and procedural issues, such as rules regarding absentee voting, to which body the monitoring committee should report officially, and the timing and general content of dissemination of different kinds of results, would make jointly sponsored trials more robust to difficulties at the final hour.
Gilpin
Adele M Kaplan
AM
Center for Clinical Trials, The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA. agilpin@jhsph.edu
Holbrook
Janet T
JT
Jabs
Douglas A
DA
Meinert
Curtis L
CL
D017088:AIDS-Related Opportunistic Infections / Q000401:mortality* / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D026661:Clinical Trials Data Monitoring Committees; D017726:Cytomegalovirus Retinitis / Q000628:therapy*; D003627:Data Interpretation, Statistical; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000592:standards / Q000706:statistics & numerical data*; D012449:Safety; D036302:Therapeutic Human Experimentation / Q000941:ethics; D014481:United States
D000911:Antibodies, Monoclonal; C409204:sevirumab